Pliva: Two Steps Forward, One Step Back?
Executive Summary
After a fervent US expanstion capped by the surprise $150 million licensing of Indevus OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales have disappointed, illustrating again the challenges of taking a specialist approach to primary care marketing. Pliva's best bet may be to switch growth engines to its promising biogenerics portfolio.
You may also be interested in...
Schwarz Shops Fesoterodine to Pfizer
Pfizer Inc.'s acquisition of worldwide rights to Schwarz's registration-stage incontinence product fesoterodine for $210 million plus royalties is the most recent milestone in the German company's successful integration of drug development to its legacy marketing organization-and one that nearly guarantees it a substantial revenue stream regardless of how fesoterodine fares in the marketplace.
Schwarz Shops Fesoterodine to Pfizer
Pfizer Inc.'s acquisition of worldwide rights to Schwarz's registration-stage incontinence product fesoterodine for $210 million plus royalties is the most recent milestone in the German company's successful integration of drug development to its legacy marketing organization-and one that nearly guarantees it a substantial revenue stream regardless of how fesoterodine fares in the marketplace.
Kos/Biovail: How a Mid-Cap Can Win in Primary Care
In May 2005 Kos Pharmaceuticals took over three of Biovail Corp's hypertension drugs plus most of its associated sales force, paying just 1.4 times 2004 sales-or roughly a fifth of what Biovail had paid for the same products less than five years ago. The deal draws attention to why the two mid-cap companies--similarly sized, and, until recently, with a similar business model--have fared so differently in primary care.